eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

4/2007
vol. 32
 
Share:
Share:
more
 
 
abstract:


Review paper
CD20 as a target for therapy

Magdalena Winiarska
,
Jacek Bil
,
Urszula Demkow
,
Maria Wąsik

(Centr Eur J Immunol 2007; 32 (4): 239-246)
Online publish date: 2007/12/10
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Rituximab is a chimeric human-mouse monoclonal antibody directed against CD20 antigen. CD20 antigen is characterisitc for precursors and mature B lymphocytes. Rituximab is thought to induce complement-mediated cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and apoptosis. Rituximab is mainly used to treat non-Hodgkin’s lymphomas, however it may prove an optimal treatment in various diseases related to autoantibody production. Beside rituximab there are other anti-CD20 antibodies: ibritumomab, tositumomab (both conjugated with radioisotopes), ofatumumab (human antibody undergoing clinical studies). The other strategies to target lymphoma cells include small peptides (mimotopes) that mimic CD20 antigen and thus force patient’s organism to produce anti-CD20 antibodies.
keywords:

rituximab, non-Hodgkin’s lymphoma, CD20 antigen, complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity

FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe